CHE Company Profile and Key Details

CHE has shown mixed momentum, gaining 0.52% over the past week and -4.68% over the past quarter, though year-to-date performance is down -18.34%. Short-term trend indicators are bullishly aligned (SMA20 0.52%, SMA50 -0.66%, SMA200 -12.65%). The stock’s 14-day RSI is 50.43 (neutral), while the ATR of 9.19 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -30.62% below its high and over 5.94% above its low. Average 10-day trading volume of 160.82 thousand shares is in line with the 3-month average of 169.64 thousand, indicating normal recent market interest.

Chemed Corporation generated EPS of $18.91 over the past year. Five-year average earnings growth is 8.37%. Wall Street analysts project EPS growth of 5.79% annually over the next five years. The latest quarter delivered EPS of $5.27. The next quarter is forecast at $7.07. Next year's EPS is expected at $11.14. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $667.00 to $500.00. The high target offers 54.16% upside. The low target suggests 15.56% downside. The mean target is $593.67. This offers 37.21% upside. Chemed Corporation earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by -2.23%. The prior quarter beat by -10.67%. Over the last six quarters, Apple has recorded several small beats. These include -1.26% in July 24, 2024.

Chemed Corporation last paid a dividend of 2.2 per share, this equals a trailing yield of roughly 0.28%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $875.71. This means the shares are trading below this model’s fair value.

Chemed Corporation has 14.57 million shares outstanding. The public float is 14.28 million shares, elevated short interest at 3.26% of float. This equals 410.22 thousand shares. The short ratio is 2.18 days. Institutional investors hold 99.95% of the float. Insiders own 1.98%. MCNAMARA KEVIN J holds 94.20 thousand shares, HUTTON THOMAS C has 32.76 thousand shares and LEE SPENCER S has 14.63 thousand shares. Over the past six months, insider transactions show net selling. They sold 17.16 thousand shares across 5 transactions.

Chemed Corporation (NYSE:CHE) closed at $432.66 USD, losing -$3.08 (-0.71%) from the previous close of $435.74. The stock is currently mid-range between its 52-week high and low $408.42 and $623.61. With a market capitalization of about $6.32 billion, Chemed Corporation is classified as a mid-cap and shows lower-than-market volatility (beta ~0.46). Key stats such as the average daily volume over the past year has been around 174.58 thousand shares, volume is running light vs its 52-week average. Headquartered in Cincinnati, OH, Chemed Corporation operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Kevin J. McNamara, the company employs approximately 15,695 people and listed since May 03, 1973. Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States.

Chemed Corporation trades at a P/E ratio of 22.56, slightly below the S&P 500 average, with a price-to-sales ratio of 2.5 and a price-to-book ratio of 5.84 trading at moderately above to book value. The P/FCF stands at 17.54, also above market averages.

Chemed Corporation (NYSE:CHE) shares are down -18.34% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Chemed Corporation trading at a premium to the broader market with a P/E of 22.56. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $381.28, suggesting -11.88% downside. Our AI forecast model points to short-term strength (2.21% over two weeks), a medium-term rise (12.35% over three months), and a longer-term loss (-2.68% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Chemed Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.21%, with price expected at $442.23 by January 05, 2026, within a range of $435.51 to $449.67 3-Month Outlook: Projected rise of 12.35%, reaching $486.10 by March 20, 2026, with a range of $468.06 to $503.37. 1-Year Outlook: Projected loss of -2.68%, with price at $421.08 by December 22, 2026, within a range of $406.10 to $443.78.